E Fund Management Co. Ltd. Invests $497,000 in Dianthus Therapeutics, Inc. $DNTH

E Fund Management Co. Ltd. purchased a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 5,094 shares of the company’s stock, valued at approximately $497,000.

Several other institutional investors and hedge funds have also bought and sold shares of DNTH. First Horizon Corp purchased a new stake in Dianthus Therapeutics in the first quarter worth $32,000. Global Retirement Partners LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $93,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics during the 4th quarter worth $40,000. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth $27,000. Finally, Russell Investments Group Ltd. purchased a new stake in Dianthus Therapeutics in the 3rd quarter worth about $64,000. 47.53% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DNTH. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, HC Wainwright raised their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 16,167 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the transaction, the senior vice president directly owned 3,833 shares of the company’s stock, valued at $423,086.54. This trade represents a 80.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Ryan Savitz sold 31,249 shares of the business’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 287,084 shares of company stock worth $29,615,923 in the last ninety days. Insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Stock Performance

Shares of DNTH opened at $109.51 on Friday. Dianthus Therapeutics, Inc. has a 52-week low of $22.76 and a 52-week high of $117.88. The stock’s 50-day simple moving average is $100.17 and its 200 day simple moving average is $84.80. The stock has a market capitalization of $5.99 billion, a price-to-earnings ratio of -26.39 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. On average, research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.